NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free IMRX Stock Alerts $1.39 +0.01 (+0.72%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$1.34▼$1.4450-Day Range$1.38▼$2.8952-Week Range$1.34▼$11.92Volume159,067 shsAverage Volume189,430 shsMarket Capitalization$41.21 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Immuneering alerts: Email Address Immuneering MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside871.2% Upside$13.50 Price TargetShort InterestBearish16.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 4 Articles This WeekInsider TradingSelling Shares$3.05 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.02) to ($1.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.52 out of 5 starsMedical Sector287th out of 928 stocksPharmaceutical Preparations Industry126th out of 437 stocks 4.3 Analyst's Opinion Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageImmuneering has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immuneering's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.80% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Immuneering has recently increased by 9.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMRX. Previous Next 1.8 News and Social Media Coverage News SentimentImmuneering has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immuneering this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have sold 1,045.28% more of their company's stock than they have bought. Specifically, they have bought $266,645.00 in company stock and sold $3,053,819.00 in company stock.Percentage Held by Insiders25.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immuneering's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($2.02) to ($1.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Immuneering's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Immuneering Stock (NASDAQ:IMRX)Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More IMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMRX Stock News HeadlinesMay 29, 2024 | globenewswire.comImmuneering to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | americanbankingnews.comImmuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 19, 2024 | morningstar.comImmuneering Corp Class A IMRXMay 17, 2024 | finanznachrichten.deUSA News Group: Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer TreatmentMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immuneering with $8 Price Target Amidst Promising Pipeline and Upcoming Data EventsMay 8, 2024 | markets.businessinsider.comBuy Rating Maintained for Immuneering Amid Promising Clinical Pipeline DevelopmentsMay 7, 2024 | globenewswire.comImmuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | finance.yahoo.comWe Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth CarefullyMay 6, 2024 | globenewswire.comImmuneering Recognizes Melanoma Awareness MonthMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed: Immuneering’s Lead Asset IMM-1-104 Shows Promise Despite Market SkepticismApril 17, 2024 | msn.comImmuneering (IMRX) Price Target Decreased by 11.43% to 13.55April 11, 2024 | investing.comImmuneering advances pancreatic cancer treatment trialApril 9, 2024 | finanznachrichten.deImmuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | globenewswire.comIMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 3, 2024 | globenewswire.comImmuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immuneering on Solid Trial Progress and Insider ConfidenceMarch 27, 2024 | globenewswire.comImmuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsMarch 21, 2024 | investing.comImmuneering CEO acquires $55.3k in company stockMarch 21, 2024 | finance.yahoo.comImmuneering Director Acquires 7.5% More StockMarch 18, 2024 | msn.comImmuneering stock rebounds 34% following last week's selloffMarch 18, 2024 | benzinga.comWhy Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 18, 2024 | msn.comCanopy Growth, Outlook Therapeutics, Immuneering among healthcare moversMarch 15, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.49%March 15, 2024 | markets.businessinsider.comImmuneering: Hold Rating Amidst Potential and Uncertainties in Drug EfficacyMarch 15, 2024 | markets.businessinsider.comCancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial DataSee More Headlines Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/02/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRX CUSIPN/A CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$25.00 Low Stock Price Target$3.00 Potential Upside/Downside+871.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,470,000.00 Net MarginsN/A Pretax Margin-5,163,499.50% Return on Equity-55.79% Return on Assets-50.47% Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio14.38 Sales & Book Value Annual Sales$320,000.00 Price / Sales128.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / Book0.52Miscellaneous Outstanding Shares29,650,000Free Float22,240,000Market Cap$41.21 million OptionableNot Optionable Beta-0.60 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Benjamin J. Zeskind M.B.A. (Age 41)Ph.D., Co-Founder, President, CEO & Director Comp: $935.09kMr. Robert J. Carpenter M.B.A. (Age 78)M.S., Co-Founder & Chair Emeritus Comp: $75.36kDr. Brett M. Hall Ph.D. (Age 55)Chief Scientific Officer Comp: $905.41kMr. Harold E. Brakewood (Age 58)Chief Business Officer Comp: $579.77kMs. Mallory Morales CPA (Age 40)Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Ms. Paula George CPADirector of Accounting & Operations and Assistant Corporate ControllerMr. Michael D. Bookman J.D. (Age 37)Chief Legal Officer & Secretary Ms. Leah R. Neufeld (Age 51)Chief People Officer Dr. Peter King Ph.D.Head of Discovery & VPDr. Praveen Nair Ph.D.Head of Translational Pharmacology & VPMore ExecutivesKey CompetitorsRapid Micro BiosystemsNASDAQ:RPIDGreenwich LifeSciencesNASDAQ:GLSILifecore BiomedicalNASDAQ:LFCRAbeona TherapeuticsNASDAQ:ABEOAlimera SciencesNASDAQ:ALIMView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDSold 2,467,834 shares on 5/15/2024Ownership: 3.070%Vanguard Group Inc.Bought 129,851 shares on 5/10/2024Ownership: 4.060%Cormorant Asset Management, LpSold 400,000 sharesTotal: $1.16 M ($2.90/share)Peter FeinbergBought 25,000 shares on 3/22/2024Total: $63,750.00 ($2.55/share)Harold Eugene BrakewoodBought 3,900 shares on 3/22/2024Total: $10,023.00 ($2.57/share)View All Insider TransactionsView All Institutional Transactions IMRX Stock Analysis - Frequently Asked Questions Should I buy or sell Immuneering stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMRX shares. View IMRX analyst ratings or view top-rated stocks. What is Immuneering's stock price target for 2024? 8 brokerages have issued 12 month target prices for Immuneering's shares. Their IMRX share price targets range from $3.00 to $25.00. On average, they anticipate the company's stock price to reach $13.50 in the next year. This suggests a possible upside of 871.2% from the stock's current price. View analysts price targets for IMRX or view top-rated stocks among Wall Street analysts. How have IMRX shares performed in 2024? Immuneering's stock was trading at $7.35 at the beginning of 2024. Since then, IMRX shares have decreased by 81.1% and is now trading at $1.39. View the best growth stocks for 2024 here. Are investors shorting Immuneering? Immuneering saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,530,000 shares, an increase of 10.0% from the April 30th total of 3,210,000 shares. Based on an average trading volume of 759,500 shares, the days-to-cover ratio is presently 4.6 days. Approximately 16.8% of the shares of the stock are short sold. View Immuneering's Short Interest. When is Immuneering's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our IMRX earnings forecast. How were Immuneering's earnings last quarter? Immuneering Co. (NASDAQ:IMRX) announced its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.04. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Immuneering's major shareholders? Immuneering's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.06%) and Price T Rowe Associates Inc. MD (3.07%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Cormorant Asset Management, Lp, Harold Eugene Brakewood, Laurie Keating, Leah R Neufeld, Mallory Morales, Michael Bookman, Peter Feinberg and Scott Barrett. View institutional ownership trends. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMRX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
